Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473102 | 0.88 | LMNA (0.39) | DRD2DRD3DRD4NAMPTDRD1 | |
| SCHEMBL17444268 | 0.66 | OPRM1 (0.56) | LMNA | |
| SCHEMBL14721849 | 0.64 | DRD3 (0.79) | DRD2DRD3DRD4DRD1 | |
| SCHEMBL14761584 | 0.62 | DRD2 (0.94) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL9427702 | 0.62 | ALDH1A1 (0.57) | L3MBTL1KMT2ALMNAMEN1 | |
| SCHEMBL16227646 | 0.62 | ALDH1A1 (0.69) | DRD2DRD3DRD4KMT2ALMNA | |
| SCHEMBL20248864 | 0.61 | DRD2 (0.60) | DRD2DRD3DRD4NAMPTDRD1 | |
| SCHEMBL4707395 | 0.61 | LMNA (0.75) | L3MBTL1NAMPTKMT2ALMNAMEN1 | |
| SCHEMBL1384427 | 0.61 | ALDH1A1 (0.72) | DRD2DRD4L3MBTL1NAMPTKMT2A | |
| SCHEMBL10720845 | 0.61 | ALDH1A1 (0.76) | DRD2DRD3DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | DRD2 3489/4885DRD3 3598/4885DRD4 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.